N-(3-甲基苯基)-9H-嘌呤-6-胺 | 82760-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: N-(3-甲基苯基)-9H-嘌呤-6-胺
• 英文名称: N-(3-methylphenyl)-7H-purin-6-amine
• CAS: 82760-82-5
• 化学式: C₁₂H₁₁N₅
• 分子量: 225.253
• InChiKey: VPNQRIINNCGTDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-deoxy-D-ribose 、 N-(3-甲基苯基)-9H-嘌呤-6-胺 在 四磷十氧化物 、 (C₄H₉)3N 、 水 作用下， 生成 (2R,4R,5S)-4-(6-m-Tolylamino-purin-9-yl)-tetrahydro-pyran-2,5-diol 、 (2S,4R,5S)-4-(6-m-Tolylamino-purin-9-yl)-tetrahydro-pyran-2,5-diol
  参考文献：
  名称：

  Andersen, Jesper; Pedersen, Erik B., Liebigs Annalen der Chemie, 1986, # 11, p. 1837 - 1846

  摘要：

  DOI：
• 作为产物：
  描述：

  间甲苯胺盐酸盐 、 次黄嘌呤 在 N,N-二甲基环己胺 、 phosphorus pentoxide 作用下， 反应 24.0h， 以50%的产率得到N-(3-甲基苯基)-9H-嘌呤-6-胺
  参考文献：
  名称：

  Phosphorus Pentoxide in Organic Synthesis; II¹. A New, One-Step Conversion of Hypoxanthine intoN ⁶-Substituted Adenines

  摘要：

  DOI：

  10.1055/s-1982-29845

文献信息

• Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
  申请人：Dolezal Karel

  公开号：US20050043328A1

  公开（公告）日：2005-02-24

  New heterocyclic derivatives based on N 6 -substituted adenine, having anticancer, mitotic, imunosuppressive and antisenescent propoerties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.

  基于N6-取代腺嘌呤的新杂环衍生物具有抗癌、有丝分裂、免疫抑制和抗衰老的性质，适用于植物、动物和人类细胞，并提供其制备方法。还包括含有这些衍生物作为活性化合物的药物组合物、化妆品制剂和生长调节剂，以及这些衍生物用于制备药物、化妆品制剂、生物技术过程、化妆品和农业的用途。
• HETEROCYCLIC COMPOUNDS BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS
  申请人：Popa Igor

  公开号：US20080014227A1

  公开（公告）日：2008-01-17

  Novel heterocyclic derivatives based on N 6 -substituted adenine, having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.

  基于N6-取代腺嘌呤的新型杂环衍生物，具有抗癌、有丝分裂、免疫抑制和抗衰老的性质，适用于植物、动物和人类细胞，以及它们的制备方法。还包括含有这些衍生物作为活性化合物的制药组合物、化妆品制剂和生长调节剂，以及使用这些衍生物制备药物、化妆品制剂、生物技术过程、化妆品和农业的方法。
• Compounds for improving mRNA splicing
  申请人：The General Hospital Corporation

  公开号：US10676475B2

  公开（公告）日：2020-06-09

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

  本文提供的化合物有助于改善细胞中的 mRNA 剪接。本文提供的示例化合物可用于改善包含至少一个以核苷酸序列 CAA 结尾的外显子的基因中的 mRNA 剪接。还提供了制备这些化合物的方法和治疗中枢神经系统疾病的方法。
• HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE
  申请人：Ustav Experimentalni Botaniky Akademie ved Ceské Republiky

  公开号：EP1419157A2

  公开（公告）日：2004-05-19
• Compounds for Improving mRNA Splicing
  申请人：The General Hospital Corporation

  公开号：US20180118748A1

  公开（公告）日：2018-05-03

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.